Literature DB >> 31678693

Spatial evaluation of prevalence, pattern and predictors of cervical cancer screening in India.

A Puranik1, S M Shreenidhi2, S N Rai3.   

Abstract

OBJECTIVE: To investigate the social determinants of cervical cancer screening and report the locations vulnerable to poor utilization of cervical cancer screening services. STUDY
DESIGN: An ecological study with the data derived from fourth round of the National Family Health Survey conducted in India in the period 2015-2016.
METHODS: The study focused on the percentage of women who have never undergone cervical cancer screening across 639 districts in India. Moran's I statistic was used to investigate the overall clustering of location. The Getis-Ord Gi* statistic was used for the detection of significant local clusters. Spatial error, spatial lag, spatial Durbin and spatial Durbin error models were compared, and the model with best fit was reported. ArcGIS, GeoDa and R software were used for the analysis.
RESULTS: The existence of spatial autocorrelation (Moran's I = 0.61) necessitates the consideration of spatial component while studying the screening data. A significant clustering of districts with poor screening has been observed in the North-Central and North-Eastern regions of India. The geographic arrangement of the percentage of women who have undergone cervical cancer screening was associated with the percentage of women with poor wealth index (P < 0.001), not using a modern method of contraception (P < 0.001), residing in rural areas (P = 0.033) and never heard of sexually transmitted infection (P = 0.014). The range of percentage of women getting cervix screened for cancer was 0.5-68.4%, presenting the heterogeneity among the population elements.
CONCLUSION: A higher risk of poor cervical cancer screening is observed in the districts where most of the women have poor wealth index, reside in urban area, have never heard of sexually transmitted infection and do not use a modern method of contraception.
Copyright © 2019 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cervical cancer screening; India; NFHS-4; Spatial epidemiology; Spatial regression

Mesh:

Year:  2019        PMID: 31678693     DOI: 10.1016/j.puhe.2019.09.008

Source DB:  PubMed          Journal:  Public Health        ISSN: 0033-3506            Impact factor:   2.427


  6 in total

1.  Cervical Cancer Screening and Associated Barriers among Women in India: A Generalized Structural Equation Modeling Approach.

Authors:  Nilima Nilima; Kalaivani Mani; Siddharth Kaushik; Shesh Nath Rai
Journal:  Cancers (Basel)       Date:  2022-06-23       Impact factor: 6.575

2.  Cervical Cancer Screening Uptake and Predictors Among Women in Jeddah, Saudi Arabia.

Authors:  Sultanah F Alsalmi; Sahar S Othman
Journal:  Cureus       Date:  2022-04-12

3.  Survival of Patients With Cervical Cancer Treated With Definitive Radiotherapy or Concurrent Chemoradiotherapy According to Histological Subtype: A Systematic Review and Meta-Analysis.

Authors:  Guorong Yao; Jian Qiu; Fengjia Zhu; Xiaoxie Wang
Journal:  Front Med (Lausanne)       Date:  2022-03-01

4.  Spatial variations and social determinants of life expectancy in China, 2005-2020: A population-based spatial panel modelling study.

Authors:  Wei Wang; Yunning Liu; Pengpeng Ye; Chengdong Xu; Yun Qiu; Peng Yin; Jiangmei Liu; Jinlei Qi; Jinling You; Lin Lin; Lijun Wang; Junming Li; Wei Shi; Maigeng Zhou
Journal:  Lancet Reg Health West Pac       Date:  2022-04-11

5.  Psycho-social factors associated with the nationwide lockdown in India during COVID- 19 pandemic.

Authors:  Nilima Nilima; Siddharth Kaushik; Bhaskar Tiwary; Piyush Kant Pandey
Journal:  Clin Epidemiol Glob Health       Date:  2020-06-30

6.  Loss to Follow-Up and the Care Cascade for Cervical Cancer Care in Rural Guatemala: A Cross-Sectional Study.

Authors:  Andrea Garcia; Michel Juarez; Neftali Sacuj; Evelyn Tzurec; Karen Larson; Ann Miller; Peter Rohloff
Journal:  JCO Glob Oncol       Date:  2022-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.